Eli Lilly’s office in San Diego, Nov. 21, 2025. Mike Blake | Reuters The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead Sciences' HIV drug Biktarvy and Pfizer's arthritis treatment Xeljanz. It is the third round of drugs subject to former President Joe Biden's Inflation Reduction Act of 2022, which allowed the government to neg...
Eli Lilly’s office in San Diego, Nov. 21, 2025. Mike Blake | Reuters The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead Sciences' HIV drug Biktarvy and Pfizer's arthritis treatment Xeljanz. It is the third round of drugs subject to former President Joe Biden's Inflation Reduction Act of 2022, which allowed the government to negotiate prices of some drugs purchased by the U.S. Medicare health program for people aged 65 and older or with disabilities. Despite the industry's longstanding opposition to the law and multiple failed lawsuits, the first negotiated prices on 10 drugs sold in pharmacies went into effect this year. The 2028 list also includes products that are administered in doctors' offices or hospitals, such as Novartis psoriasis drug Cosentyx and Botox, which is made by AbbVie. Other medications up for negotiation include Eli Lilly's GLP-1 diabetes drug Trulicity. "With prior rounds of pricing negotiations reasonable, and several of these medicines set to lose exclusivity in the near-term, we continue to expect that the impacts will be manageable," said BMO Capital Markets analyst Evan Seigerman. The U.S. Medicare health plan said last year that the prices it had negotiated for 15 drugs starting in 2027 would save the program 36% on those medications compared with recent annual spending, or about $8.5 billion. Shares of Gilead, Lilly, AbbVie, Johnson & Johnson, Pfizer and Bristol Myers were all up nearly 2% in after-hours trading. Gilead's HIV treatment Biktarvy, which had 2024 sales of $13.4 billion, had been expected to be on the negotiation list. The company in October said it had reached settlements with three generic manufacturers, extending the drug's U.S. patent coverage to April 2036. "While we expect Biktarvy will likely be eligible for IRA price negotiations beginning in 2028, only a low-20% of US sales are expected to be exposed," JP Morgan said in a research note at that tim...
The entire executive committee of Malaysia’s football association resigned on Wednesday, the latest blow in a damaging eligibility row over forged documents used to field foreign-born players in Asian Cup qualifiers. Fifa suspended seven foreign-born players for a year in September and fined the Football Association of Malaysia (FAM) US$400,000 for submitting false documents claiming they had Mala...
The entire executive committee of Malaysia’s football association resigned on Wednesday, the latest blow in a damaging eligibility row over forged documents used to field foreign-born players in Asian Cup qualifiers. Fifa suspended seven foreign-born players for a year in September and fined the Football Association of Malaysia (FAM) US$400,000 for submitting false documents claiming they had Malaysian ancestry. Football’s global governing body had launched an investigation after receiving a complaint following Malaysia’s 4-0 thrashing of Vietnam in a June Asian Cup qualifier. Advertisement “The resignations are to safeguard the reputation and institutional interests of [the association] and to mitigate the risk of further adverse consequences that could affect Malaysian football as a whole,” Yusoff Mahadi, FAM’s acting president, told reporters. FAM appealed the sanctions, but a Fifa committee rejected it and issued a scathing report slamming the association for “not taking any discernible disciplinary action”. Advertisement It ordered a full investigation into FAM’s conduct and governance.
Kawasaki Heavy Industries Chairman of The Board Yoshinori Kanehana discusses how a strong yen may affect his company's business. He speaks with Menaka Doshi from the sidelines of India Energy Week 2026. (Source: Bloomberg)
Kawasaki Heavy Industries Chairman of The Board Yoshinori Kanehana discusses how a strong yen may affect his company's business. He speaks with Menaka Doshi from the sidelines of India Energy Week 2026. (Source: Bloomberg)
台中養殖場涉隱瞞禽流感疫情 當局表明將處罰 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】台灣台中市有養殖場涉嫌隱瞞禽流感疫情，當局表明將處罰。 涉事養殖場位於豐原區，當地傳媒報道早前有居民在網上指目睹養殖場掩埋...
台中養殖場涉隱瞞禽流感疫情 當局表明將處罰 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】台灣台中市有養殖場涉嫌隱瞞禽流感疫情，當局表明將處罰。 涉事養殖場位於豐原區，當地傳媒報道早前有居民在網上指目睹養殖場掩埋大量死亡雞隻，台中市政府周一晚接獲通報後周二派員採集樣本，至周三確認為禽流感疫情。當局已成立前進指揮所，撲殺場內所有雞隻，並對周邊半徑3公里範圍內的養殖場進行消毒，同時追查已流出雞蛋的去向。針對養殖場私自掩埋死亡雞隻，農業局強調行為已違規，將處以新台幣5萬元以上、100萬元以下的罰款。
US Representative Ilhan Omar was charged at by a man who appeared to squirt an unknown liquid on her during a town hall gathering in Minneapolis. (Source: Bloomberg)
US Representative Ilhan Omar was charged at by a man who appeared to squirt an unknown liquid on her during a town hall gathering in Minneapolis. (Source: Bloomberg)
LG Display press release ( LPL ): Q4 EBITDA in the fourth quarter of 2025 was KRW 1,162 billion, compared with EBITDA of KRW 1,424 billion in the third quarter of 2025 and KRW 1,306 billion in the fourth quarter of 2024. Net loss in the fourth quarter of 2025 was KRW 351 billion, compared with the net profit of 1 billion in the third quarter of 2025 and with the net loss of KRW 839 billion in the ...
LG Display press release ( LPL ): Q4 EBITDA in the fourth quarter of 2025 was KRW 1,162 billion, compared with EBITDA of KRW 1,424 billion in the third quarter of 2025 and KRW 1,306 billion in the fourth quarter of 2024. Net loss in the fourth quarter of 2025 was KRW 351 billion, compared with the net profit of 1 billion in the third quarter of 2025 and with the net loss of KRW 839 billion in the fourth quarter of 2024. Revenue of KRW 7201B (-8.1% Y/Y). OLED products accounted for a record-high 61% of total revenues in 2025. The OLED revenue share has shown consistent growth, rising from 32% in 2020, to 40% in 2022, and 55% in 2024. In 2025, LG Display’s exit from the large-sized LCD business further accelerated its strategic shift from LCD to OLED. More on LG Display LG Display Is Turning Its Biggest Problem Into Its Greatest Strength LG Display Co., Ltd. 2025 Q3 - Results - Earnings Call Presentation LG Display Co., Ltd. (LPL) Q3 2025 Earnings Call Transcript LG Display Q4 2025 Earnings Preview Seeking Alpha’s Quant Rating on LG Display